US FDA accepts for review new drug application for reltecimod for the treatment of suspected organ dysfunction or failure in patients with necrotizing soft tissue infection

Reltecimod is a small synthetic peptide that binds to the dimer interface of CD28 expressed on T-cells, thereby modulating the acute inflammation that leads to systemic organ failure. The application is based on data from the ACCUTE Phase III placebo-controlled trial.

Source:

Biospace Inc.